Allovir Net Income vs Operating Income Analysis

ALVR Stock

USD 0.54 0.01 1.89%

Allovir financial indicator trend analysis is way more than just evaluating Allovir prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Allovir is a good investment. Please check the relationship between Allovir Net Income and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allovir. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Allovir Stock, please use our How to Invest in Allovir guide.

Net Income vs Operating Income

Net Income vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Allovir Net Income account and Operating Income. At this time, the significance of the direction appears to have totally related.

The correlation between Allovir's Net Income and Operating Income is 1.0. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Operating Income in the same time period over historical financial statements of Allovir, assuming nothing else is changed. The correlation between historical values of Allovir's Net Income and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Allovir are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Net Income i.e., Allovir's Net Income and Operating Income go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Allovir financial statement analysis. It represents the amount of money remaining after all of Allovir operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Operating Income

Operating Income is the amount of profit realized from Allovir operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Allovir is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Allovir's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Allovir current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allovir. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Allovir Stock, please use our How to Invest in Allovir guide.At this time, Allovir's Issuance Of Capital Stock is relatively stable compared to the past year. As of 11/28/2024, Sales General And Administrative To Revenue is likely to grow to 60.81, while Selling General Administrative is likely to drop slightly above 33.9 M.

	2021	2022	2023	2024 (projected)
Interest Income	1.3M	1.9M	5.3M	5.5M
Net Interest Income	1.3M	1.9M	5.3M	5.5M

Interest Income Net Interest Income

Allovir fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Long Term Debt Total	Property Plant And Equipment Net
Total Assets		0.62	0.79	0.96	0.94	-0.93	-0.87	-0.65	0.65	0.91	0.72	0.55	0.59	1.0	-0.19	0.48	-0.35	-0.92	0.95	0.83	-0.11	0.96	1.0	0.99	0.61	0.27
Other Current Liab	0.62		0.68	0.54	0.47	-0.6	-0.86	-0.17	0.6	0.8	0.9	0.31	0.93	0.58	-0.35	0.23	-0.01	-0.55	0.52	0.41	0.17	0.54	0.58	0.56	0.5	0.79
Total Current Liabilities	0.79	0.68		0.75	0.79	-0.82	-0.84	-0.82	0.97	0.92	0.76	0.11	0.68	0.77	-0.63	0.77	-0.37	-0.79	0.7	0.88	-0.07	0.75	0.77	0.72	0.89	0.39
Total Stockholder Equity	0.96	0.54	0.75		0.98	-0.8	-0.84	-0.64	0.63	0.86	0.64	0.39	0.51	0.96	-0.32	0.38	-0.59	-0.79	0.97	0.88	-0.38	1.0	0.96	0.96	0.59	0.26
Net Tangible Assets	0.94	0.47	0.79	0.98		-0.81	-0.81	-0.72	0.7	0.84	0.59	0.36	0.46	0.94	-0.34	0.5	-0.6	-0.8	0.93	0.94	-0.38	0.98	0.94	0.93	0.62	0.17
Current Deferred Revenue	-0.93	-0.6	-0.82	-0.8	-0.81		0.79	0.72	-0.7	-0.86	-0.72	-0.61	-0.57	-0.92	0.1	-0.69	0.07	1.0	-0.82	-0.77	-0.22	-0.8	-0.92	-0.9	-0.66	-0.22
Net Debt	-0.87	-0.86	-0.84	-0.84	-0.81	0.79		0.48	-0.78	-0.98	-0.77	-0.4	-0.89	-0.86	0.38	-0.37	0.33	0.76	-0.76	-0.7	0.09	-0.84	-0.86	-0.84	-0.58	-0.46
Retained Earnings	-0.65	-0.17	-0.82	-0.64	-0.72	0.72	0.48		-0.78	-0.64	-0.42	0.02	-0.17	-0.64	0.52	-0.87	0.44	0.72	-0.63	-0.87	0.16	-0.64	-0.65	-0.61	-0.85	0.03
Accounts Payable	0.65	0.6	0.97	0.63	0.7	-0.7	-0.78	-0.78		0.85	0.63	-0.01	0.68	0.63	-0.67	0.77	-0.39	-0.67	0.53	0.81	-0.1	0.63	0.64	0.58	0.83	0.28
Cash	0.91	0.8	0.92	0.86	0.84	-0.86	-0.98	-0.64	0.85		0.8	0.35	0.82	0.89	-0.44	0.52	-0.35	-0.84	0.8	0.79	-0.07	0.86	0.89	0.87	0.71	0.42
Non Current Assets Total	0.72	0.9	0.76	0.64	0.59	-0.72	-0.77	-0.42	0.63	0.8		0.23	0.7	0.67	-0.44	0.46	-0.09	-0.67	0.7	0.61	0.12	0.64	0.67	0.65	0.75	0.83
Non Currrent Assets Other	0.55	0.31	0.11	0.39	0.36	-0.61	-0.4	0.02	-0.01	0.35	0.23		0.34	0.58	0.68	0.04	0.4	-0.64	0.42	0.11	0.46	0.39	0.57	0.61	-0.18	-0.09
Other Assets	0.59	0.93	0.68	0.51	0.46	-0.57	-0.89	-0.17	0.68	0.82	0.7	0.34		0.57	-0.31	0.21	-0.03	-0.54	0.4	0.36	0.16	0.51	0.56	0.54	0.39	0.53
Cash And Short Term Investments	1.0	0.58	0.77	0.96	0.94	-0.92	-0.86	-0.64	0.63	0.89	0.67	0.58	0.57		-0.15	0.46	-0.36	-0.92	0.95	0.82	-0.12	0.96	1.0	1.0	0.56	0.22
Net Receivables	-0.19	-0.35	-0.63	-0.32	-0.34	0.1	0.38	0.52	-0.67	-0.44	-0.44	0.68	-0.31	-0.15		-0.38	0.66	0.05	-0.25	-0.54	0.51	-0.32	-0.16	-0.11	-0.74	-0.47
Common Stock Shares Outstanding	0.48	0.23	0.77	0.38	0.5	-0.69	-0.37	-0.87	0.77	0.52	0.46	0.04	0.21	0.46	-0.38		-0.05	-0.69	0.39	0.72	0.22	0.38	0.46	0.42	0.82	0.06
Non Current Liabilities Total	-0.35	-0.01	-0.37	-0.59	-0.6	0.07	0.33	0.44	-0.39	-0.35	-0.09	0.4	-0.03	-0.36	0.66	-0.05		0.05	-0.49	-0.61	0.94	-0.59	-0.36	-0.35	-0.37	-0.03
Inventory	-0.92	-0.55	-0.79	-0.79	-0.8	1.0	0.76	0.72	-0.67	-0.84	-0.67	-0.64	-0.54	-0.92	0.05	-0.69	0.05		-0.81	-0.76	-0.23	-0.79	-0.91	-0.9	-0.62	-0.15
Other Current Assets	0.95	0.52	0.7	0.97	0.93	-0.82	-0.76	-0.63	0.53	0.8	0.7	0.42	0.4	0.95	-0.25	0.39	-0.49	-0.81		0.84	-0.29	0.97	0.95	0.95	0.62	0.34
Other Stockholder Equity	0.83	0.41	0.88	0.88	0.94	-0.77	-0.7	-0.87	0.81	0.79	0.61	0.11	0.36	0.82	-0.54	0.72	-0.61	-0.76	0.84		-0.37	0.88	0.83	0.8	0.82	0.21
Total Liab	-0.11	0.17	-0.07	-0.38	-0.38	-0.22	0.09	0.16	-0.1	-0.07	0.12	0.46	0.16	-0.12	0.51	0.22	0.94	-0.23	-0.29	-0.37		-0.38	-0.13	-0.13	-0.1	0.03
Net Invested Capital	0.96	0.54	0.75	1.0	0.98	-0.8	-0.84	-0.64	0.63	0.86	0.64	0.39	0.51	0.96	-0.32	0.38	-0.59	-0.79	0.97	0.88	-0.38		0.96	0.96	0.59	0.26
Total Current Assets	1.0	0.58	0.77	0.96	0.94	-0.92	-0.86	-0.65	0.64	0.89	0.67	0.57	0.56	1.0	-0.16	0.46	-0.36	-0.91	0.95	0.83	-0.13	0.96		1.0	0.57	0.22
Net Working Capital	0.99	0.56	0.72	0.96	0.93	-0.9	-0.84	-0.61	0.58	0.87	0.65	0.61	0.54	1.0	-0.11	0.42	-0.35	-0.9	0.95	0.8	-0.13	0.96	1.0		0.52	0.2
Short Long Term Debt Total	0.61	0.5	0.89	0.59	0.62	-0.66	-0.58	-0.85	0.83	0.71	0.75	-0.18	0.39	0.56	-0.74	0.82	-0.37	-0.62	0.62	0.82	-0.1	0.59	0.57	0.52		0.48
Property Plant And Equipment Net	0.27	0.79	0.39	0.26	0.17	-0.22	-0.46	0.03	0.28	0.42	0.83	-0.09	0.53	0.22	-0.47	0.06	-0.03	-0.15	0.34	0.21	0.03	0.26	0.22	0.2	0.48

Click cells to compare fundamentals

Allovir Account Relationship Matchups

Allovir fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	139.4M	370.8M	286.6M	277.1M	190.8M	236.5M
Other Current Liab	5.4M	4.9M	15.3M	6.9M	44K	41.8K
Total Current Liabilities	9.1M	12.3M	37.9M	24.3M	28.4M	21.2M
Total Stockholder Equity	(51.5M)	353.1M	225.3M	224.5M	145.8M	158.9M
Net Tangible Assets	(51.5M)	353.1M	225.3M	224.5M	258.2M	158.6M
Net Debt	(49.3M)	(114.0M)	(171.6M)	(70.7M)	(62.7M)	(65.8M)
Retained Earnings	(55.3M)	(125.1M)	(297.1M)	(465.8M)	(656.2M)	(623.4M)
Accounts Payable	630K	963K	8.4M	3.0M	6.8M	3.6M
Cash	61.1M	122.7M	201.7M	106.1M	90.1M	110.7M
Non Current Assets Total	12.1M	9.5M	33.2M	34.0M	3.2M	3.0M
Cash And Short Term Investments	126.1M	356.3M	248.1M	233.8M	183.9M	214.6M
Net Receivables	560K	450K	50K	157K	206K	230K
Common Stock Shares Outstanding	65.1M	26.9M	62.8M	76.7M	104.1M	68.3M
Short Term Investments	65.0M	233.7M	46.5M	127.7M	93.8M	103.9M
Liabilities And Stockholders Equity	139.4M	370.8M	286.6M	277.1M	190.8M	236.5M
Non Current Liabilities Total	181.8M	5.5M	23.5M	28.2M	16.6M	15.8M
Capital Lease Obligations	11.8M	8.7M	30.1M	35.4M	27.4M	20.8M
Other Current Assets	676K	9.5M	5.2M	9.1M	3.5M	5.1M
Other Stockholder Equity	(169.4M)	478.3M	522.5M	690.8M	802.0M	416.7M
Total Liab	190.9M	17.8M	61.3M	52.6M	45.0M	56.5M
Net Invested Capital	(51.5M)	353.1M	225.3M	224.5M	145.8M	158.9M
Total Current Assets	127.3M	361.3M	253.3M	243.1M	187.6M	219.6M
Net Working Capital	118.2M	349.0M	215.5M	218.7M	159.3M	198.4M

Pair Trading with Allovir

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.

Moving against Allovir Stock

0.47	NAMS	NewAmsterdam Pharma	Pair Corr
0.43	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.42	MNOV	MediciNova	Pair Corr

The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.

The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Allovir Stock Analysis

When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC